CytoSorbents Corporation

1.91-0.0600-3.05%Vol 183.53K1Y Perf -75.38%
Aug 12th, 2022 16:00 DELAYED
BID1.85 ASK1.95
Open2.00 Previous Close1.97
Pre-Market- After-Market-
 - -  - -%
Target Price
10.50 
Analyst Rating
Strong Buy 1.00
Potential %
449.74 
Finscreener Ranking
★★★★+     54.99
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★★     46.47
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★★+     49.53
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
2.71 
Earnings Rating
Neutral
Market Cap82.43M 
Earnings Date
2nd Aug 2022
Alpha-0.00 Standard Deviation0.16
Beta0.37 

Today's Price Range

1.882.00

52W Range

1.699.80

5 Year PE Ratio Range

-21.50-14.70

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-9.05%
1 Month
-16.96%
3 Months
-15.11%
6 Months
-49.07%
1 Year
-75.38%
3 Years
-63.27%
5 Years
-58.48%
10 Years
-

TickerPriceChg.Chg.%
CTSO1.91-0.0600-3.05
AAPL172.123.63002.15
GOOG122.652.83002.36
MSFT291.914.89001.70
XOM94.000.81000.87
WFC45.940.69001.52
JNJ165.30-1.8400-1.10
FB196.640.99000.51
GE79.931.03001.31
JPM122.131.99001.66
 
ProfitabilityValueIndustryS&P 500US Markets
66.30
-91.90
-87.70
-76.20
-91.55
RevenueValueIndustryS&P 500US Markets
33.86M
0.78
20.36
28.64
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.14-0.25-78.57
Q01 2022-0.15-0.21-40.00
Q04 2021-0.13-0.21-61.54
Q03 2021-0.12-0.15-25.00
Q02 2021-0.03-0.11-266.67
Q01 2021-0.03-0.10-233.33
Q04 2020-0.020.00100.00
Q03 2020-0.09-0.0277.78
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.146.67Positive
9/2022 QR-0.1229.41Positive
12/2022 FY-0.589.38Positive
12/2023 FY-0.40-14.29Negative
Next Report Date-
Estimated EPS Next Report-0.14
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume183.53K
Shares Outstanding43.16K
Shares Float42.57M
Trades Count1.20K
Dollar Volume351.14K
Avg. Volume155.15K
Avg. Weekly Volume128.36K
Avg. Monthly Volume90.74K
Avg. Quarterly Volume246.35K

CytoSorbents Corporation (NASDAQ: CTSO) stock closed at 1.91 per share at the end of the most recent trading day (a -3.05% change compared to the prior day closing price) with a volume of 183.53K shares and market capitalization of 82.43M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 156 people. CytoSorbents Corporation CEO is Phillip P. Chan.

The one-year performance of CytoSorbents Corporation stock is -75.38%, while year-to-date (YTD) performance is -54.42%. CTSO stock has a five-year performance of -58.48%. Its 52-week range is between 1.69 and 9.8, which gives CTSO stock a 52-week price range ratio of 2.71%

CytoSorbents Corporation currently has a PE ratio of -2.40, a price-to-book (PB) ratio of 1.81, a price-to-sale (PS) ratio of 2.51, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -41.98%, a ROC of -47.90% and a ROE of -58.32%. The company’s profit margin is -91.55%, its EBITDA margin is -87.70%, and its revenue ttm is $33.85 Million , which makes it $0.78 revenue per share.

Of the last four earnings reports from CytoSorbents Corporation, there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.14 for the next earnings report. CytoSorbents Corporation’s next earnings report date is -.

The consensus rating of Wall Street analysts for CytoSorbents Corporation is Strong Buy (1), with a target price of $10.5, which is +449.74% compared to the current price. The earnings rating for CytoSorbents Corporation stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CytoSorbents Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CytoSorbents Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 24.79, ATR14 : 0.18, CCI20 : -126.00, Chaikin Money Flow : -0.39, MACD : -0.06, Money Flow Index : 44.13, ROC : -15.49, RSI : 33.20, STOCH (14,3) : 10.91, STOCH RSI : 0.73, UO : 36.70, Williams %R : -89.09), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CytoSorbents Corporation in the last 12-months were: Al W. Kraus (Buy at a value of $9 795), Alan D. Sobel (Buy at a value of $20 175), Edward R. Jones (Buy at a value of $3 749), Edward R. Jones (Option Excercise at a value of $16 500), Kathleen P. Bloch (Buy at a value of $36 449), Michael G. Bator (Buy at a value of $6 610), Phillip P. Chan (Buy at a value of $91 393), Vincent Capponi (Buy at a value of $39 528)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

CytoSorbents Corporation

CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries.The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend, K ontrol, and DrugSorb. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending.

CEO: Phillip P. Chan

Telephone: +1 732 329-8885

Address: 7 Deer Park Drive, Monmouth Junction 08852, NJ, US

Number of employees: 156

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

57%43%

Bearish Bullish

58%42%


News

Stocktwits